ProBioGen and ImmunOs Therapeutics have extended their partnership for further large-scale manufacturing of clinical material for IOS-1002, ImmunOs' lead program for the treatment of cancer. ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' biologic.
ProBioGen and ImmunOs Therapeutics announce the extension of their partnership for further large-scale manufacturing of clinical material for IOS-1002, ImmunOs' lead program for the treatment of cancer. ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' innovative biologic.
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, announced that the company has received full ethical institutional approval from the Human Research Ethics Committee (HREC) and regulatory approval from the Therapeutic Goods Administration (TGA) to conduct a phase 1 trial of its lead programme IOS-1002 in Australia. The first patients are expected to be enrolled in Q1, 2023.
Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – October 4, 2022 – ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced that Joseph Leveque, MD, has been appointed to the Company´s Board of Directors.
Zurich-area biotech ImmunOs Therapeutics reeled in a $74 million Series B to take that lead program into a Phase Ia study in Australia toward the end of this year, executives told Endpoints News. The drug, dubbed IOS-1002, is a multi-agent based on human leukocyte antigens (HLAs) that go after two versions of LILRB (1 and 2) and KIR3DL1.
ImmunOs Therapeutics AG, a Swiss bio-technology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced that is has received public funding from the European Union’s Eurostars-2 Programme and the Swiss Innovation Agency Innosuisse. The funds have been granted for the development of a pioneering HLA-open conformer-specific antibody to treat chronic inflammatory rheumatic diseases. Research will be conducted by a consortium with ProteoGenix SAS (Strasbourg, France) and Amsterdam University Medical Centres (Amsterdam, The Netherlands).
ImmunOs Therapeutics AG, a Swiss bio-technology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced that is has received public funding from the European Union’s Eurostars-2 Programme and the Swiss Innovation Agency Innosuisse. The funds have been granted for the development of a pioneering HLA-open conformer-specific antibody to treat chronic inflammatory rheumatic diseases. Research will be conducted by a consortium with ProteoGenix SAS (Strasbourg, France) and Amsterdam University Medical Centres (Amsterdam, The Netherlands).
ImmunOs Therapeutics will use ProBioGen’s proprietary Pathway Modulator Technology for the development of its pipeline of novel complex recombinant proteins.
ImmunOs Therapeutics will use ProBioGen’s proprietary Pathway Modulator Technology for the development of its pipeline of novel complex recombinant proteins.